Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00797823 · ClinicalTrials.gov registry record · Phase 2
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
A Phase 2 study of Type 1 Diabetes, sponsored by Legacy Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00797823: Completed Phase 2 study of Type 1 Diabetes, sponsored by Legacy Health System.
NCT00797823 is a Phase 2 study of Type 1 Diabetes that has completed, run by Legacy Health System. The registered enrollment target is 14 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00797823, a Phase 2 study of Type 1 Diabetes, has completed, sponsored by Legacy Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system. This combined glucose sensing/hormone delivery approach is a step on the way to eventual development of an artificial (or automated) pancreas. The insulin and glucagon delivery algorithm is based on the difference between the current blood glucose and the target glucose (proportional error) and the rate of change in blood glucose (derivative error), both adjusted for the recent glucose history. This algorithm is called the Fading Memory Proportional-Derivative (FMPD) Algorithm. The principal investigator of this study has published previous research regarding the use of this algorithm and found it to be well-suited to control blood glucose in type 1 diabetic animals. The addition of glucagon was helpful; better glycemic control with fewer glucose excursions were observed when small intermittent infusions of subcutaneous glucagon were given during times of impending low blood sugar (Ward et al. 2008).
Primary Outcome
Effectiveness of closed loop diabetes control will be measured by mean glucose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Glucagon
- DRUG Insulin, Asp(B28)-
Study Locations (1)
Oregon
- Legacy Research - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00797823 record still lists
NCT00797823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00797823 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00797823 about?
NCT00797823 is a clinical study titled "Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone". This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system. This combined glucose sensing/hormone delivery approach is a step on the way to eventual development of an artificial (or automated) pancreas. The insuli...
What is the current status of trial NCT00797823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2008-11. Estimated completion is 2009-09.
What conditions does trial NCT00797823 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT00797823?
The interventions under investigation include: Placebo (DRUG), Glucagon (DRUG), Insulin, Asp(B28)- (DRUG).
Who is sponsoring clinical trial NCT00797823?
This trial is sponsored by Legacy Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00797823 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00797823's enrollment target sits among peer trials
14 170th of 198 higher than 27 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
RECRUITING · Phase 2
-
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
RECRUITING · Phase 2
-
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
RECRUITING · Phase 2
-
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia